These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 18952518

  • 1. grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin- methicillin-resistant Staphylococcus aureus.
    Coskun-Ari FF, Bosgelmez-Tinaz G.
    Eur J Med Res; 2008 Aug 18; 13(8):366-70. PubMed ID: 18952518
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [A study on the resistance of Staphylococcus aureus and the mechanisms of its resistance to fluoroquinolone].
    Lei Y, Gui X, Feng G.
    Zhonghua Nei Ke Za Zhi; 2001 Mar 18; 40(3):176-9. PubMed ID: 11798575
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
    Schmitz FJ, Fluit AC, Brisse S, Verhoef J, Köhrer K, Milatovic D.
    FEMS Immunol Med Microbiol; 1999 Dec 18; 26(3-4):281-7. PubMed ID: 10575140
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE.
    Antimicrob Agents Chemother; 1999 Aug 18; 43(8):1845-55. PubMed ID: 10428901
    [Abstract] [Full Text] [Related]

  • 9. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
    Roychoudhury S, Catrenich CE, McIntosh EJ, McKeever HD, Makin KM, Koenigs PM, Ledoussal B.
    Antimicrob Agents Chemother; 2001 Apr 18; 45(4):1115-20. PubMed ID: 11257024
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of quinolone resistance in Staphylococcus aureus.
    Tanaka M, Wang T, Onodera Y, Uchida Y, Sato K.
    J Infect Chemother; 2000 Sep 18; 6(3):131-9. PubMed ID: 11810552
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619.
    Watanabe S, Ito T, Hiramatsu K.
    J Antimicrob Chemother; 2007 Dec 18; 60(6):1384-7. PubMed ID: 17890283
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR.
    J Antimicrob Chemother; 2009 Dec 18; 64(6):1226-9. PubMed ID: 19833635
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.